Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Moderna

Submit next-generation COVID-19 vaccine mRNA-1283 for approval

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
12 Sep 2024
Due
31 Dec 2024
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The Company expects to file for approval in 2024 and intends to use a Priority Review Voucher.”
  • SourceModerna Form 8-K press release, 2024-09-12
  • FilingSEC filing index
  • Deadline as statedin 2024
  • Deadline used31 Dec 2024, the last day of the stated period
  • TypeRegulatory
  • Permanent referenceKI-C-2024-MRNA-006225
    Cite as https://keptindex.org/c/KI-C-2024-MRNA-006225/ — this address never changes.

What we found

Evidence strength A What the grades mean

Later filings state Moderna filed mRNA-1283 for FDA approval in Q4 2024 using a priority review voucher, within the 2024 deadline; the exact filing date is not given.

  • A
    Moderna 10-K filed 2025-02-21 Regulatory filing · published 21 Feb 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint e2b7c6073e1a
    “During the fourth quarter of 2024, we achieved significant milestones in our respiratory vaccine portfolio. We filed for regulatory approval with the FDA for our next-generation COVID vaccine (mRNA-1283)” ✓ confirmed on the page
  • A
    Moderna 10-Q filed 2025-05-01 Regulatory filing · published 1 May 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint c83f7cc6e909
    “We filed for regulatory approval of mRNA-1283 with the FDA using a priority review voucher in 2024.” ✓ confirmed on the page

Market reaction: the shares moved +1.3% against the S&P 500 over the three sessions around the disclosure (20 Feb 2025 to 25 Feb 2025). What this measures

Checked 10 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Regulatory other
Indicative materiality
Medium rules
Action
Submit
Deliverable
Next-generation COVID-19 vaccine mRNA-1283 regulatory filing
Language
Aspirational (“aims”, “intends”)
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-MRNA-006225 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.